Flumazenil is a benzodiazepine inhibitor Flumazenil are used as reversal drug for postsurgical sedation from benzodiazepine anesthetics. Flumazenil injection is recommended for a complete or partial reversal of the sedative effects of benzodiazepines in conscious sedation and general anesthesia in adult and pediatric populations.
Flumazenil is also designated for the management and treatment of benzodiazepine overdose in adults. It is used in reversing coma due to benzodiazepine overdose. Flumazenil is more effective in reversing coma in benzodiazepine intoxication than patients with multiple drug overdoses.
Market Dynamics
Increasing research and development for the treatment of coma using flumazenil is expected to propel growth of the global flumazenil market. For instance, according to research data published on May 9, 2021, in Journal of Medical Case Reports, researchers have reported that flumazenil has showed positive result in complete neurocognitive recovery of patient with a Glasgow Coma Score of 15. 0.25 mg of flumazenil was intravenously administered to the patient who was unresponsive with Glass Coma Score of 3. After the patient was directed with flumazenil, the patient completely recovered by neurocognitive.
Increasing cases of people facing drowsiness problem is expected to drive growth of the global flumazenil market, over the forecast period. For instance, according to data published by European Transport Workers’ Federation, in 2019 a survey done in city of London, reported that among 1353 bus drivers 37% of the drivers had to fight with drowsiness in order to stay awake. Flumazenil is used for the treatment of patients suffering from drowsiness. Flumazenil injections given through vein are more effective to treat people facing drowsiness.
Key features of the study:
- This report provides an in-depth analysis of the global flumazenil market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global flumazenil market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Hoffmann La Roche, Akorn-Strides, LLC, Sandoz Canada Incorporated, Fresenius Kabi USA, LLC, Mylan Pharmaceuticals, Genentech, Inc., General Injectables & Vaccines Inc, Sina Health Inc, West Ward Pharmaceutical, HF Acquisition Co. LLC, DBA HealthFirst, Hikma Farmaceutica, Pfizer Laboratories Div Pfizer Inc., Physicians Total Care, Inc., and Bedford Pharmaceuticals
- Insights from this report would allow marketers and management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global flumazenil market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global flumazenil market.
Detailed Segmentation:
- Global Flumazenil Market, By Dose:
- Global Flumazenil Market, By Application:
- Anti - Sedation
- Reversing Drowsiness
- Others (Hepatic Encephalopathy, Cirrhosis)
- Global Flumazenil Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Flumazenil Market, By Region:
- North America
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Hoffmann La Roche *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Akorn-Strides, LLC
- Sandoz Canada Incorporated
- Fresenius Kabi USA, LLC
- Mylan Pharmaceuticals
- Genentech, Inc.
- General Injectables & Vaccines Inc
- Sina Health Inc
- West Ward Pharmaceutical
- HF Acquisition Co. LLC, DBA HealthFirst
- Hikma Farmaceutica
- Pfizer Laboratories Div Pfizer Inc.
- Physicians Total Care, Inc.
- Bedford Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.
